Wenlei Li

Title: Innovations of Wenlei Li in Biological Pharmacy

Introduction

Wenlei Li is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biological pharmacy, particularly through his innovative work on fusion proteins. His research focuses on developing long-acting therapeutic agents that can address various medical conditions.

Latest Patents

Wenlei Li holds a patent for the HM-3 fusion protein and its applications. This invention pertains to a long-acting HM-3 fusion protein molecule, which is designed to enhance the therapeutic efficacy of small peptides. The fusion protein is characterized by its ability to prolong the half-life of HM-3, making it a promising candidate for treating autoimmune diseases, neovascular diseases, and osteoarthritis. The general formula of the molecular entity includes combinations of HM-3, linker peptides, and Fc (IgG) fragments, which together create a novel molecular entity that is both cost-effective and highly functional.

Career Highlights

Wenlei Li is associated with Tasly Biopharmaceuticals Co., Ltd., where he continues to advance his research in biological pharmacy. His work has garnered attention for its potential to revolutionize treatment options for various diseases.

Collaborations

Wenlei Li collaborates with esteemed colleagues such as Ruijing Huang and Baoqing Fan, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Wenlei Li's contributions to the field of biological pharmacy through his patent on the HM-3 fusion protein exemplify the impact of innovative research on healthcare. His work not only addresses critical medical challenges but also paves the way for future advancements in therapeutic solutions.